Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
DH.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XGNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GE.1.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.58.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.8.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.1.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDD.1.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDNNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LT.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.8.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LV.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.54.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.30.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.1.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
MN.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.63NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LE.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LH.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HW.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.55.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.18.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDK.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.3.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.2.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LS.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.1 (Omicron)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4 (Omicron)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.5.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HD.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FD.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.2.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.2.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FK.1.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FT.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBF.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.1.25NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAGNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.1.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used